Literature DB >> 15447998

Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.

Jie Wang1, J Jack Lee, Luo Wang, Diane D Liu, Charles Lu, You-Hong Fan, Waun Ki Hong, Li Mao.   

Abstract

The p16INK4a and RASSF1A are tumor suppressor genes frequently inactivated by de novo promoter hypermethylation in non-small cell lung cancer. We studied 119 patients with non-small cell lung cancer (70 stage I/II and 49 stage IIIA) who had undergone surgery with curative intent. The p16INK4a and RASSF1A promoter methylation statuses were determined by methylation-specific PCR. Statistical analyses, all two-sided, were performed to determine the prognostic effect of hypermethylation on various clinical parameters. Hypermethylation of the p16INK4a and RASSF1A promoters was found in 58 (49%) and 46 (39%) tumors, respectively, and 30 tumors (25%) exhibited hypermethylation of both gene promoters. In patients with stage I/II tumors, only p16INK4a promoter hypermethylation was associated with a poor 5-year overall survival rate (P=0.002). In patients with stage IIIA disease, however, RASSF1A promoter hypermethylation was a stronger predictor of a poor 5-year overall survival rate (P < 0.0001) than p16INK4a promoter hypermethylation. Among the 49 patients with stage IIIA tumors, 16 (89%) of the 18 patients whose tumors showed RASSF1A promoter hypermethylation died within 3 years after surgery, as compared with only 12 (39%) of the 31 patients whose tumors had no RASSF1A promoter hypermethylation (P < 0.0001). Multivariate analysis indicated that RASSF1A promoter hypermethylation was the stronger independent predictor for survival in patients with locally advanced non-small cell lung cancer. Our results indicate that p16INK4a promoter hypermethylation predicts a poor 5-year survival rates for patients with resectable non-small cell lung cancer, particularly for those with early stage tumors, whereas RASSF1A promoter hypermethylation is a profound prognostic predictor for patients with locally advanced non-small cell lung cancer, suggesting an important role of RASSF1A in non-small cell lung cancer progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15447998     DOI: 10.1158/1078-0432.CCR-04-0652

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  p16 hypermethylation: a biomarker for increased esophageal cancer susceptibility in high incidence region of North East India.

Authors:  Mandakini Das; Bhaskar Jyoti Saikia; Santanu Kumar Sharma; Gaganpreet Singh Sekhon; Jagadish Mahanta; Rup Kumar Phukan
Journal:  Tumour Biol       Date:  2014-11-01

Review 2.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

3.  Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma.

Authors:  Milena Krajnović; Milica Radojković; Radoslav Davidović; Bogomir Dimitrijević; Koviljka Krtolica
Journal:  Med Oncol       Date:  2012-12-30       Impact factor: 3.064

4.  A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers.

Authors:  Alexander Drilon; Hirofumi Sugita; Camelia S Sima; Marjorie Zauderer; Charles M Rudin; Mark G Kris; Valerie W Rusch; Christopher G Azzoli
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

Review 5.  Molecular biology of lung cancer: clinical implications.

Authors:  Jill E Larsen; John D Minna
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

6.  The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis.

Authors:  L van der Weyden; K K Tachibana; M A Gonzalez; D J Adams; B L Ng; R Petty; A R Venkitaraman; M J Arends; A Bradley
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

7.  Identification of an epigenetic profile classifier that is associated with survival in head and neck cancer.

Authors:  Graham M Poage; Rondi A Butler; E Andrés Houseman; Michael D McClean; Heather H Nelson; Brock C Christensen; Carmen J Marsit; Karl T Kelsey
Journal:  Cancer Res       Date:  2012-04-16       Impact factor: 12.701

Review 8.  Aberrant methylation in non-small cell lung cancer.

Authors:  Makoto Suzuki; Ichiro Yoshino
Journal:  Surg Today       Date:  2010-06-26       Impact factor: 2.549

Review 9.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

10.  Clinical correlates of promoter hypermethylation of four target genes in head and neck cancer: a cooperative group correlative study.

Authors:  Jong-Lyel Roh; Xin Victoria Wang; Judith Manola; David Sidransky; Arlene A Forastiere; Wayne M Koch
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.